A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease

BACKGROUND: Ustekinumab was approved for moderate and severe Crohn’s disease (CD) in 2016, but little is known about long-term outcomes. METHODS: A retrospective study evaluated all patients with CD treated with ustekinumab, including patients with reinduction. C-reactive protein (CRP), Harvey-Brads...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Crohns Colitis 360
Main Authors: Bennett, Audrey, Evers Carlini, Lauren, Duley, Caroline, Garrett, Ailish, Annis, Kim, Wagnon, Julianne, Dalal, Robin, Scoville, Elizabeth, Beaulieu, Dawn, Schwartz, David, Horst, Sara
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Observations and Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7067228/
https://ncbi.nlm.nih.gov/pubmed/32201860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/crocol/otaa013
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados